Content about Pharmaceutical sciences

December 5, 2012

Walgreens last month acquired UCH Pharmaceutical Services, an independent retail pharmacy based in Indiana, the company that helped broker the deal announced Wednesday.

ADDISON, Texas — Walgreens last month acquired UCH Pharmaceutical Services, an independent retail pharmacy based in Indiana, the company that helped broker the deal announced Wednesday. 

UCH is an independent retail pharmacy that provided specialty compounding services throughout Grant County, Ind. 

The Transition Companies acted as UCH’s sole M&A advisor for this transaction, which closed in November 2012.

 

 

December 4, 2012

The Food and Drug Administration will review an acid-reflux drug made by Eisai for use in children, the drug maker said.

WOODCLIFF LAKE, N.J. — The Food and Drug Administration will review an acid-reflux drug made by Eisai for use in children, the drug maker said.

Eisai said the FDA accepted its application for AcipHex delayed-release sprinkle capsules in the 5-mg and 10-mg strengths for healing of gastroesophageal reflux disease, and maintenance of healing of GERD and improvement of symptoms in children ages 1 year to 11 years.

The FDA expects to have the application reviewed by March 27, 2013. The drug is currently approved in the 20-mg strength for adolescents and adults.

December 4, 2012

Pharmacy technology provider QS/1 has entered a contract with CoverMyMeds to automate a process often required by insurers to dispense specialty drugs.

SPARTANBURG, S.C. – Pharmacy technology provider QS/1 has entered a contract with CoverMyMeds to automate a process often required by insurers to dispense specialty drugs.

QS/1 said it entered a partnership with CoverMyMeds to automate the prior-authorization process, required for 90% of specialty drugs on the market.

"A pharmacist can spend a lot of time cutting through the red tape to get these prescriptions filled," QS/1 pharmacy market analyst John Frady said. "CoverMyMeds helps cut down on that work load by automating the process."

December 4, 2012

Amid the glacial pace of change in government and health policy, congressional number crunchers have finally acknowledged an indisputable fact long known to health and pharmacy experts: prescription medicines save money.

Amid the glacial pace of change in government and health policy, congressional number crunchers have finally acknowledged an indisputable fact long known to health and pharmacy experts: prescription medicines save money.

It seems obvious enough. But it was only last week, near the end of November, that the Congressional Budget Office unveiled the results of a new study showing that greater prescription drug access and utilization can reduce health care costs in other areas, including hospitalizations.

December 3, 2012

Merck has started a clinical trial that it hopes will eventually enroll 1,700 patients to evaluate an experimental drug for Alzheimer's disease, the company said.

WHITEHOUSE STATION, N.J. — Merck has started a clinical trial that it hopes will eventually enroll 1,700 patients to evaluate an experimental drug for Alzheimer's disease, the company said.

Merck announced the start of "EPOCH," a combined phase-2 and phase-3 study of the drug MK-8931, a 78-week trial in which patients will take either the drug in the 12-mg, 40-mg or 60-mg doses or placebo.

November 30, 2012

The Food and Drug Administration has approved a new drug made by Exelixis for treating thyroid cancer, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Exelixis for treating thyroid cancer, the agency said.

The FDA announced the approval of Cometriq (cabozatinib) to treat medullary thyroid cancer — a cancer that develops in cells in the thyroid gland that make calcitonin, a hormone that helps maintain a healthy level of calcium in the blood — that has spread to other parts of the body. Another drug to treat medullary thyroid cancer, AstraZeneca's Caprelsa (vandetanib), was approved last year.

November 30, 2012

Increasing the prescriptions filled by Medicare beneficiaries by 1% would reduce the program's spending on medical services by about 0.2% by reducing costs in such areas as hospitalizations, according to a new report by the Congressional Budget Office.

WASHINGTON — Increasing the prescriptions filled by Medicare beneficiaries by 1% would reduce the program's spending on medical services by about 0.2% by reducing costs in such areas as hospitalizations, according to a new report by the Congressional Budget Office.

November 30, 2012

A new report shows that drug makers lose nearly $200 billion per year from medication nonadherence, illustrating that it's not just the healthcare system overall that loses when people don't take their medications properly.

This just goes to show the important role that pharmacy retailers have in helping to promote medication adherence by having pharmacists play an active role in patients' health care through services like medication therapy management.

A new report shows that drug makers lose nearly $200 billion per year from medication nonadherence, illustrating that it's not just the healthcare system overall that loses when people don't take their medications properly.

November 29, 2012

Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


Just how much of an impact the loss of patent protection can have on a blockbuster drug became clear earlier this year.


November 29, 2012

The Food and Drug Administration approved a new generic drug made by Mylan for urinary disorders, the company said Thursday.

PITTSBURGH — The Food and Drug Administration approved a new generic drug made by Mylan for urinary disorders, the company said Thursday.

Mylan announced the approval and launch of tolterodine tartrate tablets in the 1-mg and 2-mg strengths. The drug is a generic version of Detrol, made by Pharmacia and Upjohn, now owned by Pfizer.

Used to treat overactive bladder, tolterodine tartrate tablets had sales of about $61.5 million during the 12-month period ended in September, according to IMS Health.

November 29, 2012

A Food and Drug Administration panel has voted to recommend approval for a Johnson & Johnson drug to treat tuberculosis while the agency has recommended accelerated approval for the drug, the company said.

RARITAN, N.J. — A Food and Drug Administration panel has voted to recommend approval for a Johnson & Johnson drug to treat tuberculosis while the agency has recommended accelerated approval for the drug, the company said.

November 29, 2012

Patent settlements between generic and branded drug companies seem like one of the most controversial and long-standing issues in the pharmaceutical world, with strong opinions on both sides.


Patent settlements between generic and branded drug companies seem like one of the most controversial and long-standing issues in the pharmaceutical world, with strong opinions on both sides.


November 29, 2012

It’s a marriage of industry icons. In June, Walgreens finally made a long-awaited leap across the Atlantic to acquire British-based Alliance Boots, one of the world’s premier retailers of pharmaceuticals, health and beauty aids, and beauty care products. 


It’s a marriage of industry icons. In June, Walgreens finally made a long-awaited leap across the Atlantic to acquire British-based Alliance Boots, one of the world’s premier retailers of pharmaceuticals, health and beauty aids, and beauty care products. 


November 29, 2012

The National Community Pharmacists Association on Wednesday released Moving Forward on a Solid Foundation: Year One Progress Report, which examines the success of the association's strategic initiative Pharmacists Advancing Medication Adherence.

ALEXANDRIA, Va. — The National Community Pharmacists Association on Wednesday released Moving Forward on a Solid Foundation: Year One Progress Report, which examines the success of the association's strategic initiative Pharmacists Advancing Medication Adherence. 

November 29, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

Watson to change brand in 2013
PARSIPPANY, N.J. — Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said. Watson, whose $5.6 billion acquisition of Actavis received approval from the Federal Trade Commission in October, said it would adopt the new name starting in 2013, with plans to start a multi-year rebranding campaign and trade under a new symbol on the New York Stock Exchange.


November 29, 2012

Ultimately, there’s no “retail pharmacy” without the “pharmacy,” and that’s true of any store that dispenses prescription drugs — whether it’s a small independent drug store, a nationwide chain, a supermarket or a mass merchandiser. But in many respects, Rite Aid is trying to make the “pharmacy” component of that phrase just a little bit bigger.


Ultimately, there’s no “retail pharmacy” without the “pharmacy,” and that’s true of any store that dispenses prescription drugs — whether it’s a small independent drug store, a nationwide chain, a supermarket or a mass merchandiser. But in many respects, Rite Aid is trying to make the “pharmacy” component of that phrase just a little bit bigger.


November 29, 2012

MediSafe Project has launched what it called the first cloud-synced mobile app to help prevent emergencies caused by over- or under-dosing medications. 


SUPPLIER NEWS — MediSafe Project has launched what it called the first cloud-synced mobile app to help prevent emergencies caused by over- or under-dosing medications. 


NCR Corp. is partnering with health kiosk maker SoloHealth to provide on-site repairs to its interactive consumer healthcare kiosks at retailers as SoloHealth rolls them out around the country. The stations provide screenings for vision, blood pressure, weight, symptoms checking, body mass index and overall health.


November 29, 2012

The entirety of Rite Aid’s marketing message can really be broken down to just two simple, yet powerful words: 
wellness empowerment. 


The entirety of Rite Aid’s marketing message can really be broken down to just two simple, yet powerful words: 
wellness empowerment. 


It is those two words that have helped inform Rite Aid’s entire wellness platform, from the introduction of its wellness+ loyalty card program in 2010 to the rollout of its new Wellness stores, beginning in 2011. It is those two words that have helped reinvigorate Rite Aid’s business — from how the store is formatted and how it looks, to the energy that pops among Rite Aid’s Wellness Ambassadors. 


November 29, 2012

The global market for generic drugs will reach more than $125 billion next year, according to a new report by a British market-research firm.

LONDON — The global market for generic drugs will reach more than $125 billion next year, according to a new report by a British market-research firm.

November 29, 2012

Generic Pharmaceutical Association president and CEO Ralph Neas called it “the most important pharmaceutical legislation since the 1984 Hatch-Waxman Act.” John Castellani, president and CEO of the Pharmaceutical Research and Manufacturers of America, said the law served “the best interests of America’s patients.”


Generic Pharmaceutical Association president and CEO Ralph Neas called it “the most important pharmaceutical legislation since the 1984 Hatch-Waxman Act.” John Castellani, president and CEO of the Pharmaceutical Research and Manufacturers of America, said the law served “the best interests of America’s patients.”


November 28, 2012

Some legislators are concerned with the way energy drinks can affect young consumers.

Some legislators are concerned with the way energy drinks can affect young consumers, especially in light of news reports linking several deaths with energy drink use.

Sens. Dick Durbin, D-Ill., and Richard Blumenthal, D-Conn., are urging the Food and Drug Administration to move quickly to review the safety of these drinks.

November 28, 2012

The Food and Drug Administration has approved a drug from Perrigo and Cobrek Pharmaceuticals for treating scalp conditions.

ALLEGAN, Mich. — The Food and Drug Administration has approved a drug from Perrigo and Cobrek Pharmaceuticals for treating scalp conditions.

Perrigo said that Cobrek, with which it is partnering, had received approval for betamethasone validate foam in the 0.12% strength. The drug is a generic version of Luxiq foam, made by GlaxoSmithKline subsidiary Stiefel Labs, and is used to treat corticosteroid-responsive skin conditions of the scalp, also known as scalp psoriasis.

The branded version of the drug has annual sales of about $40 million, according to Perrigo.

November 28, 2012

As New York City enjoyed the first snowfall of the winter season, industry leaders gathered for the 14th annual Industry Issues Summit to discuss the top issues and trends impacting the industry, including the importance of seizing “whitespaces.”

NEW YORK — As New York City enjoyed the first snowfall of the winter season, industry leaders gathered for the 14th annual Industry Issues Summit to discuss the top issues and trends impacting the industry, including the importance of seizing “whitespaces.”

The all-day event was held on Tuesday at the New York Athletic Club, located just across the street from Central Park.

November 28, 2012

The Food and Drug Administration will review the safety of energy drinks containing such stimulants as caffeine in response to a letter from two senators.

WASHINGTON — The Food and Drug Administration will review the safety of energy drinks containing such stimulants as caffeine in response to a letter from two senators.

November 28, 2012

Smart Insurance on Wednesday announced it is working with Walgreens to offer in-store consultations with licensed SmartD Rx plan agents, available at select Walgreens to speak with Medicare beneficiaries who are either enrolling in a new Part D prescription drug plan or evaluating their current coverage options.

CLEVELAND — Smart Insurance on Wednesday announced it is working with Walgreens to offer in-store consultations with licensed SmartD Rx plan agents, available at select Walgreens to speak with Medicare beneficiaries who are either enrolling in a new Part D prescription drug plan or evaluating their current coverage options.